With the resolution of shortages for GLP-1 medications like Ozempic and Zepbound, the compounded versions that many turned to are now uncertain. Demand for these drugs had led to a surge in online telehealth providers offering lower-cost alternatives during the shortage. However, as pharmaceutical companies re-establish their supplies, compounding pharmacies must cease production of these alternatives. Patients who relied on these compounded medications, like Michael Futter, are faced with limited options and higher costs, exposing the fragile nature of access to vital medications.
As the primary supply chain stabilizes, many are left without access to the compounded versions that had previously been their only option for weight loss medications.
The surge in popularity of drugs like Ozempic has led to a thriving market for compounded versions, which may now be coming to an end with renewed drug availability.
Collection
[
|
...
]